🇺🇸 FDA

Intelligence · Clinical Pipeline

Sarepta Therapeutics Pipeline

All ClinicalTrials.gov programs at Sarepta Therapeutics — phase, modality, and trial IDs.

Programs
18

Quick answer

Sarepta Therapeutics has 18 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. AVI-4065 Injection

    Sarepta Therapeutics

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  2. AVI-4658 (Eteplirsen)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule completed

    1 trial

  3. AVI-4658 (Eteplirsen)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  4. AVI-4658 (PMO)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  5. AVI-4658 for Injection

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  6. AVI-5126

    Sarepta Therapeutics

    Cardiovascular Disease

    phase 2 small molecule terminated

    1 trial

  7. Amondys 45

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  8. Eteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    2 trials

  9. Placebo

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  10. Placebo - Sodium Chloride 9 mg/ml (0.9%) - Solution for injection, ARO-DM1

    Sarepta Therapeutics

    Type 1 Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  11. RESTEN-MP

    Sarepta Therapeutics

    Coronary Artery Disease

    phase 2 small molecule completed

    2 trials

  12. SODIUM CHLORIDE, ARO-DUX4

    Sarepta Therapeutics

    Facioscapulohumeral muscular dystrophy (FSHD)

    phase 2 small molecule active

    1 trial

  13. SRP-5051

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 2 small molecule terminated

    2 trials

  14. SRP-9003

    Sarepta Therapeutics

    Limb-Girdle Muscular Dystrophy, Type 2E

    phase 2 gene therapy terminated

    1 trial

  15. SRP-9004

    Sarepta Therapeutics

    Limb-Girdle Muscular Dystrophy, Type 2D

    phase 2 gene therapy completed

    1 trial

  16. VESLETEPLIRSEN(SRP-5051)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  17. Vesleteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  18. delandistrogene moxeparvovec

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 2 gene therapy active

    2 trials

Frequently asked questions

How many pipeline programs does Sarepta Therapeutics have?

18 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.